miR-146a, which targets Fas, was shown to be involved in the pathogenesis of autoimmune lymphoproliferative syndrome (ALPS) [53], whereas the miR-196b-induced reduction in FAS expression significantly promoted leukemogenesis [54]. Here, FAS is linked to autoimmune lymphoproliferative syndrome.